Immunomic Therapeutics Receives FDA Fast Track Designation f

ROCKVILLE, Md.--(BUSINESS WIRE)--#FTD--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to t...

Related Keywords

Rockville , Maryland , United States , Melissa Kemp , Therapeutics Inc , Drug Administration , Immunomic Therapeutics Inc , Immunomic Therapeutics , Fast Track Designation , William Hearl , Chief Executive Officer , Intracellular Targeted Expression , Lysosome Associated Membrane Protein , Track Designation , Lysosomal Associated Membrane Protein , Private Securities Litigation Reform Act ,